Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
dc.contributor.author | Clarke, Noel W | |
dc.contributor.author | Ali, Adnan | |
dc.contributor.author | Ingleby, FC | |
dc.contributor.author | Hoyle, Alex P | |
dc.contributor.author | Amos, CL | |
dc.contributor.author | Attard, G | |
dc.contributor.author | Brawley, CD | |
dc.contributor.author | Calvert, J | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Cook, A | |
dc.contributor.author | Cross, W | |
dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Douis, H | |
dc.contributor.author | Gilbert, D | |
dc.contributor.author | Gillessen, Silke | |
dc.contributor.author | Jones, RJ | |
dc.contributor.author | Langley, RE | |
dc.contributor.author | MacNair, A | |
dc.contributor.author | Malik, Z | |
dc.contributor.author | Mason, MD | |
dc.contributor.author | Matheson, D | |
dc.contributor.author | Millman, R | |
dc.contributor.author | Parker, CC | |
dc.contributor.author | Ritchie, AWS | |
dc.contributor.author | Rush, H | |
dc.contributor.author | Russell, JM | |
dc.contributor.author | Brown, J | |
dc.contributor.author | Beesley, S | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Capaldi, L | |
dc.contributor.author | Gale, J | |
dc.contributor.author | Gibbs, S | |
dc.contributor.author | Lydon, A | |
dc.contributor.author | Nikapota, A | |
dc.contributor.author | Omlin, A | |
dc.contributor.author | O'Sullivan, JM | |
dc.contributor.author | Parikh, O | |
dc.contributor.author | Protheroe, A | |
dc.contributor.author | Rudman, S | |
dc.contributor.author | Srihari, NN | |
dc.contributor.author | Simms, M | |
dc.contributor.author | Tanguay, JS | |
dc.contributor.author | Tolan, S | |
dc.contributor.author | Wagstaff, J | |
dc.contributor.author | Wallace, J | |
dc.contributor.author | Wylie, James P | |
dc.contributor.author | Zarkar, A | |
dc.contributor.author | Sydes, MR | |
dc.contributor.author | Parmar, MKB | |
dc.contributor.author | James, ND | |
dc.date.accessioned | 2019-11-19T15:54:52Z | |
dc.date.available | 2019-11-19T15:54:52Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019. | en |
dc.identifier.pmid | 31560068 | en |
dc.identifier.doi | 10.1093/annonc/mdz396 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622354 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz396 | en |
dc.title | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial | en |
dc.type | Article | en |
dc.contributor.department | Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | Open access article | en] |
refterms.dateFOA | 2019-11-19T15:54:52Z |